Dyadic International (DYAI) Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/7/2026
- Rivian Automotive (RIVN) files for 75M share offering
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Coursera plans layoffs after Udemy merger, estimates $8M-$11M in costs
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025 8:30 AM ESTJUPITER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Dyadic, we, us, our, or the Company) (Nasdaq: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, provided an update on its business development efforts related to its Alternative Proteins business and emerging interest in leveraging the C1 platform in the diagnostic and vaccine space to address a variety of infectious diseases, such as the H5N1 Avian Influenza (Bird Flu) outbreak. The Company also... More

